References
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, At: www.ginasthma.com NIH publication 02-3659 issued January 1995 (updated November 2007; accessed 1 December 2007)
- National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, At: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf NIH Publication 07-4051. Originally printed July 1997. Revised August 2007
- Beeh K M, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled β 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007; 29: 871–878
- Chuchalin A G, Tsoi A N, Richter K, Krug N, Dahl R, Luursema P B, Cameron R, Bao W, Higgins M, Woessner R, van As A. Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study. Respir Med 2007; 101: 2065–2075
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, At: www.ginasthma.com NIH publication 02-3659 issued January 1995 (updated April 2002; accessed 29 November 2006)
- Bensch G, Lapidus R J, Levine B E, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19–27
- Pearlman D S, Greos L, LaForce C, Orevillo C J, Owen R, Higgins M H. Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008, (in press)
- Quebe-Fehling E, Brambilla R, Bromly C L, Fishwick K, Walters E H, Hendrick D J. The duration of action of inhaled formoterol dry powder. Br J Clin Pract 1996; 50: 446–449
- Sykes A P, Ayres J G. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med 1990; 84: 135–138
- Bartow R A, Brogden R N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55: 303–322
- Venables T L, Addlestone M B, Smithers A J, Blagden M D, Weston D, Gooding T, Carr EP on behalf of the PROOF research group. A comparison of the efficacy and patient acceptability of once daily budesonide via turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μ g in adult asthmatics. Br J Clin Res 1996; 7: 15–32
- Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–1310